Clinical Trial Update: Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study [Phase 2]

View source ↗

Summary

This Phase 2 feasibility trial of risk-based therapy for sickle cell disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Snippet

Sponsor: Children's National Research Institute | Conditions: Sickle Cell Anemia | Phase 2 | Status: WITHDRAWN